Mitaprex®

Mirtazapine 7.5 mg, 15 mg & 30 mg tablet

Presentation

Mitaprex® 7.5 mg: Each tablet contains Mirtazapine USP 7.5 mg
Mitaprex® 15 mg: Each tablet contains Mirtazapine USP 15 mg
Mitaprex® 30 mg: Each tablet contains Mirtazapine USP 30 mg

Description

Mitprex (Mirtazapine) is a tetracyclic antidepressant belongs to piperazine-azepine group of compounds. The mechanism of action is unknown. Studies suggest that Mirtazapine enhances central noradrenergic and serotonergic activity. Mirtazapine acts as an antagonist at central presynaptic alpha-2 adrenergic inhibitory auto receptors and heteroreceptors that result in an increase central noradrenergic and serotonergic activity. Mirtazapine is a potent antagonist of 5 HT_2 and $5HT_3$ receptors.

Indications

Mitaprex (Mirtazapine) is indicated for the treatment of depression.

Dosage and Administration

Adult: Initially, 15 mg daily; may be increased gradually depending on clinical response. Change dose at intervals of at least 1-2 weeks. Usual effective dose: 15-45 mg daily given as single dose, preferably at bedtime, or in 2 divided doses. It can be taken with or without food.
Children: Safety and efficacy not established.
Geriatric: Use with caution.

Side effects

The most commonly reported adverse effects with mirtazapine are increase in appetite, weight gain, edema, drowsiness or sedation, dizziness, headache etc.

Precautions

Mirtazapine should be used cautiously in patients with epilepsy or history of seizure, history of mania /hypomania, patients with hepatic or renal impairment; cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery.

Pregnancy and Lactation

Mirtazapine Should not be used during pregnancy and lactation.

Contraindications

Mirtazapine is contraindicated in patients with hypersensitivity. Do not use with or within 2 weeks of stopping an MAOI; at least 1 week should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).

Drug Interactions

Mirtazapine potentiates sedative effects with alcohol or benzodiazepines, increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone), reduced plasma levels with carbamazepine and other inducers of CYP3A4 and increased bioavailability with cimetidine.

Storage

Store at 15-30°C. Protect from light and moisture.

Commercial pack

Mitaprex® 7.5 mg: Each box contains 3 blister strips of 10 tablets
Mitaprex® 15 mg: Each box contains 3 blister strips of 10 tablets
Mitaprex® 30 mg: Each box contains 3 blister strips of 10 tablets

Manufactured by
Incepta Pharmaceuticals Ltd
Savar, Dhaka, Bangladesh

V.N. 02
MR1